您的购物车当前为空
别名 NSC736630, Apogossypol
(+)-Apogossypol is an antagonist of pan-BCL-2. (+)-Apogossypol binds to Mcl-1(Bcl-2 and Bcl-xL with EC50s of 2.6, 2.8 and 3.69 μM, respectively).

(+)-Apogossypol is an antagonist of pan-BCL-2. (+)-Apogossypol binds to Mcl-1(Bcl-2 and Bcl-xL with EC50s of 2.6, 2.8 and 3.69 μM, respectively).
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 12,800 | 8-10周 | |
| 50 mg | ¥ 16,800 | 8-10周 | |
| 100 mg | ¥ 21,500 | 8-10周 |
(+)-Apogossypol 相关产品
| 产品描述 | (+)-Apogossypol is an antagonist of pan-BCL-2. (+)-Apogossypol binds to Mcl-1(Bcl-2 and Bcl-xL with EC50s of 2.6, 2.8 and 3.69 μM, respectively). |
| 靶点活性 | BCL-XL:3.69 μM (EC50), Bcl-2:2.8 μM (EC50), MCL1:2.6 μM (EC50) |
| 体外活性 | Consistent with NMR binding and fluorescence polarization assay (FPAs) data, (+)-Apogossypol showed an effective binding affinity for Bcl-xL (Kd: 1.7 μM) [1].To investigate the inhibitory effects of (+)-Apogossypol and Gossypol on LNCaP cell survival, the MTT assay is performed. (+)-Apogossypol inhibits the proliferation of LNCaP cells in a time- and dose-dependent manner, in a similar way with Gossypol. The concentration for 50% inhibition (IC50) on LNCaP cells within ~72 h is 9.57 μM, while the IC50 of Gossypol on LNCaP cells is 10.35 μM[2]. |
| 体内活性 | The anti-cancer effect of (+)-Apogossypol is evaluated in mice bearing subcutaneous LNCaP cell xenografts. The tumor growth is monitored and measured by a caliper and balance. The survival rate of the mice is notably improved by (+)-Apogossypol. Of note, the tumor sizes are also markedly decreased by (+)-Apogossypol treatment (P<0.01)[2]. |
| 别名 | NSC736630, Apogossypol |
| 分子量 | 462.53 |
| 分子式 | C28H30O6 |
| CAS No. | 66389-74-0 |
| 密度 | 1.335 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容